diagnostic radiation exposures during and before pregnancy. Am J Obstet Gynecol. 2009;200:4-24.

- Zanotti-Fregonara P, Hindie E. Performing nuclear medicine examinations in pregnant women. *Phys Med.* 2017;43:159–164.
- Zanotti-Fregonara P. Pregnancy should not rule out ¹⁸FDG PET/CT for women with cancer. *Lancet.* 2012;379:1948.
- Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med. 2008;49:853–860.
- Gear JI, Cox MG, Gustafsson J, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. *Eur J Nucl Med Mol Imaging*. 2018;45:2456–2474.
- Zanotti-Fregonara P, Jan S, Champion C, et al. In vivo quantification of 18f-fdg uptake in human placenta during early pregnancy. *Health Phys.* 2009;97:82–85.
- Vandenberghe S, Moskal P, Karp JS. State of the art in total body PET. *EJNMMI* Phys. 2020;7:35.
- Zanotti-Fregonara P, Chen K, Liow JS, Fujita M, Innis RB. Image-derived input function for brain PET studies: many challenges and few opportunities. *J Cereb Blood Flow Metab.* 2011;31:1986–1998.

- Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal radiation dose from ¹⁸F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR. *J Nucl Med.* 2015;56: 1218–1222.
- Takalkar AM, Khandelwal A, Lokitz S, Lilien DL, Stabin MG. ¹⁸F-FDG PET in pregnancy and fetal radiation dose estimates. *J Nucl Med.* 2011;52: 1035–1040.
- Zanotti-Fregonara P, Jan S, Taieb D, et al. Absorbed ¹⁸F-FDG dose to the fetus during early pregnancy. J Nucl Med. 2010;51:803–805.
- Zanotti-Fregonara P, Koroscil TM, Mantil J, Satter M. Radiation dose to the fetus from [¹⁸F]-FDG administration during the second trimester of pregnancy. *Health Phys.* 2012;102:217.
- Calais J, Hapdey S, Tilly H, Vera P, Chastan M. Hodgkin's disease staging by FDG PET/CT in a pregnant woman. *Nucl Med Mol Imaging*. 2014;48: 244–246.
- 26. Erdogan EB, Ekmekcioglu O, Vatankulu B, Ergul N, Demir M, Sonmezoglu K. An unknown pregnancy at term detected by a FDG-PET/CT study in a patient with Hodgkin's lymphoma: a case report. *Rev Esp Med Nucl Imagen Mol.* 2015;34: 201–202.

Erratum

In the article "Choice Is Good at Times: The Emergence of [⁶⁴Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [⁶⁸Ga]Ga-DOTATATE," by Jha et al. (*J Nucl Med.* 2022;63:1300–1301), gallium-68 was incorrectly cited at editing as having a lower positron energy and lower positron range than copper-64. The corrected sentence should read: "*Copper-64 has a lower positron energy than Gallium-68 (0.65 vs. 1.90 MeV), resulting in a lower positron range (0.56 vs. 3.5 mm) that provides superior spatial resolution, improved imaging quality, and enhanced detection of small lesions (7)." We regret the error.*